Company Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa.
The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.
In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015.
Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
| Country | United States |
| IPO Date | Sep 19, 1980 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 84 |
| CEO | Dr. Vishwas Seshadri M.B.A., Ph.D. |
Contact Details
Address: 6555 Carnegie Ave, 4th Floor Cleveland, Ohio 44103 United States | |
| Phone | 646-813-4701 |
| Website | abeonatherapeutics.com |
Stock Details
| Ticker Symbol | ABEO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000318306 |
| CUSIP Number | 00289Y107 |
| ISIN Number | US00289Y2063 |
| Employer ID | 83-0221517 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Joseph Walter Vazzano CPA | Chief Financial Officer |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Senior Vice President and General Counsel |
| Brian Kevany Ph.D. | Senior Vice President, Chief Technology Officer and CSO |
| Gregory Gin | Vice President of Investor Relations and Corporate Communications |
| Alison Hardgrove | Vice President of Human Resources |
| Jon Voss | Vice President and Head of Quality |
| Dmitriy Grachev M.D., Ph.D. | Chief Medical Officer |
| Dr. Madhav Vasanthavada M.B.A., Ph.D. | Senior Vice President, Chief Commercial Officer and Head of Business Development |
| Carl Denny | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 18, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 10-K | Annual Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 8, 2024 | 8-K | Current Report |